1 – 10 of 14
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Research Protocol for an Observational Health Data Analysis on the Adverse Events of Systemic Treatment in Patients with Metastatic Hormone-sensitive Prostate Cancer : Big Data Analytics Using the PIONEER Platform
(
- Contribution to journal › Article
- 2023
-
Mark
Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14)
(
- Contribution to journal › Article
- 2022
-
Mark
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer : Results from the Prospective, International, Observational Prostate Cancer Registry
(
- Contribution to journal › Article
- 2019
-
Mark
High levels of cartilage oligomeric matrix protein in the serum of breast cancer patients can serve as an independent prognostic marker
(
- Contribution to journal › Article
- 2018
-
Mark
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer : Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial
(
- Contribution to journal › Article
-
Mark
Docetaxel promotes the generation of anti-tumorigenic human macrophages
(
- Contribution to journal › Article
- 2016
-
Mark
A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent
(
- Contribution to journal › Scientific review
- 2011
-
Mark
Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: Satellite-A phase II study from the Swedish Lung Cancer Study Group
(
- Contribution to journal › Article
- 2010
-
Mark
Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
(
- Contribution to journal › Article
- 2007
-
Mark
Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer
(
- Contribution to journal › Article